---
title: "SYNERGY: Obtained the Korean Drug Registration Certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236002578.md"
description: "SYNERGY recently obtained the drug registration certificate for Amlodipine Besylate issued by the South Korean Ministry of Food and Drug Safety, marking the product's qualification for market access in South Korea. The certificate was applied for by Jiangxi SYNERGY Pharmaceutical Co., Ltd. and is applicable for the treatment of adult primary hypertension. This move will actively promote the company's business expansion in the international market"
datetime: "2025-04-15T08:38:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236002578.md)
  - [en](https://longbridge.com/en/news/236002578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236002578.md)
generator: "portal-rs"
---

# SYNERGY: Obtained the Korean Drug Registration Certificate

SYNERGY announced that the company recently received the drug registration certificate for Mesilate Potassium issued by the South Korean Ministry of Food and Drug Safety. The manufacturer's name is Jiangxi SYNERGY Pharmaceutical Co., Ltd., and the manufacturer's address is Jiangxi Province, Fengxin High-tech Industrial Park. The certification scope is for Mesilate Potassium active pharmaceutical ingredient, with the certificate number 2025-A1-0844, issued on 2025.04.14. Mesilate Potassium is suitable for the treatment of adult primary hypertension. The company's Mesilate Potassium product obtaining the drug registration certificate in South Korea marks that the company's Mesilate Potassium active pharmaceutical ingredient has gained access to the South Korean market, which will play a positive role in further expanding the company's international market business

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [Alibaba’s AI Spending Spree Intensifies — Surprise Stock Sale Has Analysts Asking Why](https://longbridge.com/en/news/296767766.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [BMS Holdings Q4 FY2026 PAT Rises 106.5% QoQ to RM5.04 Million](https://longbridge.com/en/news/296892849.md)
- [Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application](https://longbridge.com/en/news/296995766.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**